Regulatory T cells have anti-inflammatory effects by diluting TNF

2008 ◽  
Vol 3 (3) ◽  
pp. 231-234
Author(s):  
Martin Aringer
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Anti Inflammatory

Anti-inflammatory effects ofArtemisia princepsin antigen-stimulated T cells and regulatory T cells

2009 ◽  
Vol 61 (8) ◽  
pp. 1043-1050 ◽  
Author(s):  
Sung HoChang ◽  
Eun Jung Jung ◽  
Youn Hee Park ◽  
Dong Gyun Lim ◽  
Na Young Ko ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Anti Inflammatory

scholarly journals The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis

2019 ◽  
Vol 14 (4) ◽  
pp. 508-524 ◽  
Author(s):  
Heike Schmitt ◽  
Julia Ulmschneider ◽  
Ulrike Billmeier ◽  
Michael Vieth ◽  
Patrizio Scarozza ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Wound Healing ◽  
T Cells ◽  
Regulatory T Cells ◽  
Th17 Cells ◽  
Experimental Colitis ◽  
Foxp3 Expression ◽  
Treg Cells ◽  
Tlr9 Agonist ◽  
Anti Inflammatory

Abstract Background and Aims The topically applied Toll-like receptor 9 [TLR9] agonist cobitolimod is a first-in-class DNA-based oligonucleotide with demonstrated therapeutic efficacy in clinical trials with ulcerative colitis [UC] patients. We here characterized its anti-inflammatory mechanism in UC. Methods Luminal cobitolimod administration was evaluated in an experimental dextran sodium sulfate [DSS]-induced colitis model. Cultured blood and mucosal cells from UC patients were treated with cobitolimod and analysed via microarray, quantitative real-time PCR, ELISA and flow cytometry. Intestinal slides of cobitolimod-treated UC patients were analysed by immunohistochemistry. Results Cobitolimod administration markedly suppressed experimental colitis activity, and microarray analyses demonstrated mucosal IL10 upregulation and suppression of IL17 signalling pathways. Cobitolimod treatment was associated with significant induction of mucosal IL10+Tr1 and Treg cells and suppression of Th17 cells. TLR9 knockout mice indicated that cobitolimod requires TLR9 signalling for IL10 induction. In UC patients, mucosal TLR9 levels correlated with severity of inflammation. Cobitolimod inhibited IL17A and IL17F, but increased IL10 and FoxP3 expression in cultured intestinal UC T cells. Cobitolimod-mediated suppression of intestinal IL17+T cells was abrogated by IL10 blockade. Furthermore, cobitolimod led to heightened IL10 production by wound healing macrophages. Immunohistochemistry in intestinal biopsies of cobitolimod-treated UC patients indicated increased presence of IL10+mononuclear and regulatory T cells, as well as reduction of IL17+cells. Conclusion Activation of TLR9 via cobitolimod might represent a novel therapeutic approach in UC, as it suppresses Th17 cells and induces anti-inflammatory IL10+macrophages and regulatory T cells, thereby modifying the dysregulated intestinal cytokine balance. Podcast This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast

Anti-inflammatory effects of Artemisia princeps in antigen-stimulated T cells and regulatory T cells

2009 ◽  
Vol 61 (8) ◽  
pp. 1043-1050 ◽  
Author(s):  
Sung Ho Chang ◽  
Eun Jung Jung ◽  
Youn Hee Park ◽  
Dong Gyun Lim ◽  
Na Young Ko ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Artemisia Princeps ◽  
Anti Inflammatory

The Anti-inflammatory Effects of IVIg: Induction and Development of Regulatory-T Cells in a Murine Model of Asthma

2010 ◽  
Vol 125 (2) ◽  
pp. AB63
Author(s):  
A.H. Massoud ◽  
J. Guay ◽  
S. Audusseau ◽  
E. Bjur ◽  
C.A. Piccirillo ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Murine Model ◽  
Anti Inflammatory

scholarly journals Immunomodulatory effect of standardized C. asiatica extract on a promotion of regulatory T cells in rats

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Supannikar Tawinwung ◽  
Dhirarin Junsaeng ◽  
Supanut Utthiya ◽  
Phisit Khemawoot
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Inflammatory Diseases ◽  
Maximum Plasma ◽  
Immunomodulatory Effects ◽  
Good Tolerability ◽  
Male Wistar Rats ◽  
Anti Inflammatory ◽  
Triterpenoid Glycosides

Abstract Background ECa 233 is a standardized extract of C. asiatica containing the triterpenoid glycosides, madecassoside to asiaticoside in the ratio of (1.5 ± 0.5):1. Anti-inflammatory activities of ECa 233 have been reported; however the immunomodulatory effects of ECa 233 on regulatory T cells, which have a pivotal role in immune regulation, has not been elucidated. Therefore, we investigated the effects of ECa 233 on regulatory T cells that may provide benefits in autoimmune and chronic inflammatory diseases. Methods ECa 233 was prepared as oral suspension in 0.5% carboxymethylcellulose and administered to male Wistar rats via oral gavage. The pharmacokinetics and toxicity of ECa 233 were evaluated. Splenic lymphocytes were isolated and analyzed by flow cytometry and qPCR to determine the immunomodulatory effects of ECa 233 on regulatory T cells. Results All rats had good tolerability to ECa 233 and other test preparations. The pharmacokinetic study showed low oral bioavailability for both triterpenoids, with the maximum plasma concentration reached at 4 h for asiaticoside and at 0.5 h for madecassoside. Multiple oral administration of ECa 233 reduced the frequency of T cells, particularly CD8 T cells in rats. ECa 233 enhanced the percentage of regulatory T cells, characterized by high expression of CD25+ and upregulation of FoxP3 gene. Conclusions The present study demonstrated that ECa 233 possesses immunosuppressive properties by enhancing regulatory T cells. These results provide in vivo evidence for the anti-inflammatory action of ECa 233, in line with previously reports, and the potential uses of ECa 233 in the treatment of chronic inflammatory and autoimmune diseases.

Sign in / Sign up

Export Citation Format

Share Document